Search company, investor...

Founded Year

2021

Stage

Debt | Alive

Total Raised

$16.09M

Last Raised

$1.09M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+79 points in the past 30 days

About Vitt

Vitt focuses on investment management. The company offers services that allow customers to invest their idle cash in Money Market Funds. These funds are managed by Goldman Sachs Asset Management and are held with a Financial Conduct Authority-regulated custodian, mitigating counterparty risk. It was founded in 2021 and is based in London, United Kingdom.

Headquarters Location

Pennine South 18-19 Hatfields

London, England, SE18DJ,

United Kingdom

07904797738

Loading...

Vitt's Product Videos

ESPs containing Vitt

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Financial Services / Digital Lending Tech

The revenue-based financing platforms market offers an innovative approach to funding for businesses seeking capital without traditional equity or debt financing and instead exchange a percentage of their future revenues. This arrangement enables entrepreneurs to access growth capital without diluting ownership or incurring fixed interest payments. These platforms use advanced algorithms and data …

Vitt named as Challenger among 15 other companies, including Clearco, Capchase, and Pipe.

Vitt's Products & Differentiators

    Revenue-based financing for SaaS founders

    Vitt operates a financing solution for companies with monthly recurring revenues. SaaS companies can advance up to 12 months of their contracted recurring revenues upfront. An application only takes 5 minutes, and applicants receive a financing offer within 24 hours of application.

Loading...

Expert Collections containing Vitt

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vitt is included in 1 Expert Collection, including Digital Lending.

D

Digital Lending

2,271 items

This collection contains companies that provide alternative means for obtaining a loan for personal or business use and companies that provide software to lenders for the application, underwriting, funding or loan collection process.

Latest Vitt News

Rare but real: The neurological risks associated with vaccines

Aug 9, 2024

In a recent review published in the journal Nature Reviews Neurology , researchers from the United Kingdom explored the links between vaccination and neurological diseases, examining examples of vaccine-related neurological risks. They emphasized that these risks are rare and discussed the potential mitigation strategies, especially considering the coronavirus disease 2019 (COVID-19) pandemic. Background Vaccination has significantly reduced infectious diseases worldwide, saving millions of lives annually. While vaccines generally have a positive benefit-risk profile, they can occasionally cause neurological disorders, ranging from mild effects like headaches to rare severe complications such as Guillain–Barré syndrome (GBS) and cerebral venous sinus thrombosis (CVST). These rare neurological risks and low-quality safety data may raise public concern and jeopardize vaccination efforts. Research on vaccine-related neurological adverse events must be accurate, transparent, and capable of rapidly identifying and addressing safety concerns. In the present review, researchers explored the connection between vaccination and neurological diseases, emphasizing the role of neurologists in identifying safety signals, managing risks, and addressing common patient concerns regarding vaccination and neurological health. Vaccine development and safety Extensive preclinical and clinical testing is required to ensure robust vaccine safety and efficacy , especially for prophylaxis. Despite thorough testing, rare neurological adverse effects may not be detected until post-marketing surveillance, which relies on spontaneous reporting systems, case reports, and various study designs like cohort, case-control, and self-controlled case series (SCCS). Understanding the benefit-risk balance between vaccination and natural infection is crucial for public health and regulatory decisions. Neurotropic complications of live vaccination Live attenuated vaccines may cause neurotropic complications, especially in immunocompromised individuals. The yellow fever vaccine can lead to neurotropic disease (YEL-AND), manifesting as meningitis or encephalitis. Oral poliovirus vaccine (OPV) can revert to a more virulent form, causing vaccine-derived poliovirus (VDPV) and vaccine-associated paralytic poliomyelitis (VAPP). Measles vaccination, particularly in immunocompromised individuals, can lead to rare cases of measles inclusion body encephalitis (MIBE), though it significantly reduces overall morbidity and mortality. Neuro-immunological sequelae of vaccination Vaccination may rarely lead to neuro-immunological conditions like GBS, transverse myelitis, and narcolepsy. GBS has been associated with adenoviral COVID-19 vaccines, though the risk is higher with natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Certain vaccines have also caused inflammation of the central nervous system, including transverse myelitis and acute disseminated encephalomyelitis. Narcolepsy was notably linked to the 2009 swine influenza vaccine. Neurovascular complications of vaccination The neurovascular complications of vaccination include serious conditions such as CVST, which was notably linked to the ChAdOx1 nCoV-19 COVID-19 vaccine. This vaccine was associated with vaccine-induced immune thrombotic thrombocytopenia (VITT). The severity of VITT led to restrictions on adenoviral vector vaccines and a shift towards messenger ribonucleic acid (mRNA) vaccines. Although mRNA COVID-19 vaccines have been associated with rare cases of hemorrhagic stroke and myocarditis, these risks are significantly lower than those posed by natural SARS-CoV-2 infection. Exacerbation of pre-existing neurological disease For multiple sclerosis, recent data show no strong link between vaccination and disease relapses, and COVID-19 vaccines have been beneficial, especially for those with advanced disability. Concerns about vaccines worsening inflammatory neuropathies like GBS have been mostly alleviated, with evidence suggesting minimal risk. Myasthenia gravis patients showed a slight increase in hospitalization risk after the ChAdOx1 nCoV-19 vaccine, but the cause remains unclear. Overall, vaccinations are generally safe, with minimal impact on conditions like epilepsy. Improving vaccine safety Improving vaccine safety, especially during pandemics, requires rapid and coordinated global efforts. It calls for solid networks linking clinical, regulatory, and scientific fields. Effective safety monitoring involves spontaneous reporting, post-authorization studies, data linkage, and research funding. Identifying issues like VITT demonstrates the importance of swift research and response. Future efforts should focus on systematic biological studies, centralized data analysis, and greater transparency to enhance vaccine safety. Vaccine-related questions in the neurology clinic In neurology clinics, patients often question whether their neurological condition was caused by vaccination. Most neurological issues occurring shortly after vaccination are coincidental, though specific conditions like VITT and GBS have established links. For individuals with neurological diseases, the benefits of vaccination usually outweigh the risks, but precautions are necessary for live vaccines. If a patient has had a rare adverse event, a detailed risk assessment is needed before considering further vaccinations, with alternatives potentially being explored. Conclusion In conclusion, the study highlights the importance of vaccines in preventing serious infections and associated neurological diseases while acknowledging that rare neurological adverse events may occur. Early and accurate identification of these events throughout vaccine development is a significant public health challenge, with neurologists playing a crucial role. Advances during the COVID-19 pandemic have improved the timely detection of safety concerns. However, there remains a gap in understanding the mechanisms behind vaccine-associated neurological effects. In the future, coordinated, global research efforts linking epidemiological studies with clinical and laboratory analyses are required to address these challenges and maintain societal trust in vaccination. Journal reference: Identifying and reducing risks of neurological complications associated with vaccination. Handunnetthi, L. et al., Nature Reviews Neurology (2024), DOI: 10.1038/s41582-024-01000-7, https://www.nature.com/articles/s41582-024-01000-7

Vitt Frequently Asked Questions (FAQ)

  • When was Vitt founded?

    Vitt was founded in 2021.

  • Where is Vitt's headquarters?

    Vitt's headquarters is located at Pennine South, London.

  • What is Vitt's latest funding round?

    Vitt's latest funding round is Debt.

  • How much did Vitt raise?

    Vitt raised a total of $16.09M.

  • Who are the investors of Vitt?

    Investors of Vitt include Speedinvest, Better Tomorrow Ventures, Max Tayenthal, Entrepreneur First, Village Global and 7 more.

  • Who are Vitt's competitors?

    Competitors of Vitt include Pipe, re:cap, Capchase, Viceversa, Levenue and 7 more.

  • What products does Vitt offer?

    Vitt's products include Revenue-based financing for SaaS founders.

Loading...

Compare Vitt to Competitors

Pipe Logo
Pipe

Pipe provides financial services specializing in non-dilutive capital solutions for businesses. It offers a modern capital platform that allows entrepreneurs to access funding based on their revenue, with payment terms. It primarily serves the financial needs of small to mid-size businesses and entrepreneurs seeking growth without equity dilution. It was formerly known as Third Base Pipe. The company was founded in 2019 and is based in San Francisco, California.

Uncapped Logo
Uncapped

Uncapped specializes in providing non-dilutive working capital financing to growing brands and online retailers. The company offers flexible financial solutions enabling businesses to fund inventory, marketing, and other growth-related expenses without giving up equity. Uncapped primarily serves the e-commerce industry, offering services to brands and retailers with a proven track record of sales and growth. It was founded in 2019 and is based in London, United Kingdom.

F
Founderpath

Founderpath is a financial services company that operates in the Software as a Service (SaaS) industry. The company provides funding solutions for SaaS founders, offering services that allow them to track customer and business metrics, get their business valuation, and secure capital without selling equity. Primarily, Founderpath caters to the needs of the SaaS industry. Founderpath was formerly known as Operation Pie. It was founded in 2019 and is based in Austin, Texas.

Levenue Logo
Levenue

Levenue is a platform focused on providing financial services in the business sector. The company offers a service that allows businesses with recurring revenue to access funding without dilution of shares. It primarily serves businesses in need of non-dilutive financing to accelerate their growth. It was founded in 2021 and is based in Breda, Netherlands.

Capchase Logo
Capchase

Capchase specializes in providing non-dilutive growth financing and payment solutions within the SaaS industry. The company offers revenue-based capital to help SaaS companies grow and scale, SaaS split payments to facilitate deal closures, and automated invoice collection to streamline cash flow management. Capchase primarily serves the SaaS industry, offering financial tools designed to accelerate sales, improve cash flow, and support customer acquisition. It was founded in 2020 and is based in New York, New York.

Clearco Logo
Clearco

Clearco specializes in providing working capital to the ecommerce sector, focusing on funding invoices and receipts for businesses. The company offers a rapid funding process that allows ecommerce businesses to receive capital in as little as 24 hours without the need for collateral, personal guarantees, or equity dilution. Clearco's services are designed to help ecommerce businesses manage cash flow and invest in growth by funding operational expenses such as inventory, marketing, and logistics. Clearco was formerly known as Clearbanc. It was founded in 2015 and is based in Toronto, Ontario.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.